Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Cancers|July 1, 2020
Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-AnalysisReza Elaidi, Letuan Phan, Delphine Borchiellini, et al.
Journal of Imaging Informatics in Medicine|July 13, 2026
Estimating Metastatic Disease Heterogeneity Using Radiomics-based Lesion Clustering and Heterogeneity Index - Application in Lung Adenocarcinoma Patients and Correlations With Patient OutcomesLetuan Phan, Lou Andrea Sitruk, Cécile Masson-Grehaigne, et al.
Diagnostic and Interventional Imaging|February 14, 2026
Beyond handcrafted radiomics in oncologic imaging: Innovations in deep, explainable, multi-site and multi-omics radiomics approachesJules Dupont, Fiona Frau, Victor Robic, et al.
Cancers|February 13, 2026
Radiological, Radiomics, and Metastatic Patterns Associated with Targetable Oncogenic Drivers on CT-Scan of Newly Diagnosed NSCLC Patients: A Comprehensive Radiogenomics ReviewLetuan Phan, Sophie Cousin, Lou Andrea Sitruk, et al.
International Journal of Cancer|May 23, 2022
Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR studyYann-Alexandre Vano, Letuan Phan, Gwenaelle Gravis, et al.
JAMA Oncology|October 26, 2023
Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical TrialStéphane Oudard, Raffaele Ratta, Eric Voog, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2022
Plasma CD27, a Surrogate of the Intratumoral CD27-CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell CarcinomaNadine Benhamouda, Ikuan Sam, Nicolas Epaillard, et al.
The Lancet. Oncology|April 7, 2022
Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trialYann-Alexandre Vano, Réza Elaidi, Mostefa Bennamoun, et al.
Pageof 1